We used this STA model to test the role of Sema3A in RA, our in vivo data demonstrated that Sema3A administration protected the progression of arthritis, and significantly decreased the osteoclastogenesis and protected the joint tissue damage. The gene discussed is SEMA3A; the disease is rheumatoid arthritis.